High Dose Ascorbic Acid Treatment of CMT1A

Key facts

Sponsor

Wayne State University

Principal Investigator

Richard A Lewis, MD

Wayne State University, Dept. of Neurology

Intervention

Ascorbic acid (Vitamin C)(drug)

Enrollment

110 enrolled

Eligibility

13-70 years · All sexes

Timeline

2007 – 2012

Study locations (3)

• Johns Hopkins University, Dept of Neurology, Baltimore, Maryland, United States
• Wayne State University, Dept of Neurology, Detroit, Michigan, United States
• University of Rochester Medical Center, Dept of Neurology, Rochester, New York, United States

Collaborators

Muscular Dystrophy Association · Charcot-Marie-Tooth Association

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Charcot-Marie-Tooth disease type 1A

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07140614
  A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
  Novartis Pharmaceuticals
• RECRUITINGNANCT07049588
  Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease
  Assistance Publique Hopitaux De Marseille
• RECRUITINGNCT07476365
  A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)
  University Medical Center Goettingen
• RECRUITINGNCT06794489
  Longitudinal Biomarkers With Selected Outcome Measures In CMT
  University Medical Center Goettingen
• ACTIVE NOT RECRUITINGNANCT02596191
  Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers
  Assistance Publique Hopitaux De Marseille

See all trials for Charcot-Marie-Tooth disease type 1A →